58498-12-7

Basic information

• Product Name: 2-(4-AMINOBENZYL)PYRIDINE
• Synonyms: 2-(4-AMINOBENZYL)PYRIDINE;2-(p-Aminobenzyl)pyridine;4-(2-Pyridinylmethyl)benzenamine;4-(pyridin-2-ylmethyl)aniline(SALTDATA: 2HCl);[4-(2-pyridylmethyl)phenyl]amine dihydrochloride;4-(pyridin-2-ylmethyl)aniline dihydrochloride;Benzenamine,4-(2-pyridinylmethyl)-
• CAS NO: 58498-12-7
• Molecular Formula: C₁₂H₁₂N₂
• Molecular Weight: 184.23708
• Mol File: 58498-12-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-AMINOBENZYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-AMINOBENZYL)PYRIDINE(58498-12-7)
• EPA Substance Registry System: 2-(4-AMINOBENZYL)PYRIDINE(58498-12-7)

Safety Data

• Hazardous Substances Data: 58498-12-7(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 19, p. 647, 1976 DOI: 10.1021/jm00227a014

Upstream product

• 87926-09-8 N-methyl-2-(p-acetamidobenzyl)pyridinium iodide 
• 109-04-6 2-bromo-pyridine 
• 87926-07-6 2-(p-Phthalimidobenzyl)pyridine 
• 63233-47-6 2-(p-Acetamidobenzyl)pyridine 
• 555-16-8 4-nitrobenzaldehdye 
• 955-44-2 2-(α-hydroxy-4-nitrobenzyl)pyridine 
• 101-82-6 2-Benzylpyridine 
• 145654-37-1 2-(α-chloro-4-nitrobenzyl)pyridine 
• 87926-10-1 N-methyl-2-(p-phthalimidobenzyl)pyridinium iodide 
• 620-87-1 2-(4-nitrobenzyl)pyridine 

Downstream Products

• 689150-46-7 2-(dimethylamino)-4-methyl-N-[4-(2-pyridinylmethyl)phenyl]benzamide 
• 229004-94-8 7-(4-methylphenyl)-N-{4-[(pyridin-2-yl)methyl]phenyl}-2,3-dihydro-1-benzoxepine-4-carboxamide 
• 408365-07-1 N-[4-(2-pyridinylmethyl)phenyl]-1,1'-biphenyl-2-carboxamide 
• 408365-09-3 4'-methyl-N-[4-(2-pyridinylmethyl)phenyl]-1,1'-biphenyl-2-carboxamide 
• 408365-08-2 4'-chloro-N-[4-(2-pyridinylmethyl)phenyl]-1,1'-biphenyl-2-carboxamide 
• 408365-54-8 N-(4-cyanophenyl)-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide 
• 408366-14-3 4'-Methoxy-N-[4-(2-pyridinylmethyl)phenyl]-1,1'-biphenyl-2-carboxamide 
• 408365-06-0 N-[4-(2-Pyridinylmethyl)phenyl]-4'-(trifluoromethyl)-1,1'-biphenyl-2-carboxamide 
• 408366-15-4 N-[4-(2-Pyridinylmethyl)phenyl]-4'-(trifluoromethoxy)-1,1'-biphenyl-2-carboxamide 
• 408366-20-1 4'-(Methylthio)-N-[4-(2-pyridinylmethyl)phenyl]-1,1'-biphenyl-2-carboxamide 
• 408366-24-5 4'-(Methylsulfonyl)-N-[4-(2-pyridinylmethyl)phenyl]-1,1'-biphenyl-2-carboxamide 
• 1062139-51-8 ethyl (2E)-2-pentanoyl-3-{[4-(pyridin-2-ylmethyl)phenyl]amino}acrylate 
• 4350-41-8 2-(4-chlorobenzyl)pyridine 
• 113-92-8 chlorphenamine maleate 

Relevant articles and documents

A hydroquinone based palladium catalyst for room temperature nitro reduction in water

A hydroquinone based palladium complex [Pd(H2L)(Cl)2] (1), acts as an efficient room temperature catalyst for reduction of nitroarenes in water as solvent. 1 also acts as a tandem catalyst for Suzuki-Miyaura cross coupling in ethanol followed by reduction of nitroarenes in one pot with a loading of 0.25 mol% catalyst.

Orally active CCR5 antagonists as anti-HIV-1 agents 2: Synthesis and biological activities of anilide derivatives containing a pyridine N-oxide moiety

In order to develop orally active CCR5 antagonists, we investigated 1-benzoxepine derivatives containing new polar substituents, such as phosphonate, phosphine oxide or pyridine N-oxide moieties, as replacements for the previoiusly reported quaternary ammonium moiety. Among these compounds, the 2-(α-hydroxybenzyl)pyridine N-oxide 5e exhibited moderate CCR5 antagonistic activity and had an acceptable pharmacokinetic profile in rats. Subsequent chemical modification was performed and compound (S)-5f possessing the (S)-configuration hydroxy group was found to be more active than the (R)-isomer. Replacement of the 1-benzoxepine ring with a 4-methylphenyl group by a 1-benzazepine ring with a 4-[2-(butoxy)ethoxy]phenyl group enhanced the activity in the binding assay. In addition, introduction of a 3-trifluoromethyl group on the phenyl group of the anilide moiety led to greatly increased activity in the HIV-1 envelope-mediated membrane fusion assay. In particular, compound (S)-5s showed the most potent CCR5 antagonistic activity (IC 50=7.2 nM) and inhibitory effect (IC50=5.4 nM) in the fusion assay, together with good pharmacokinetic properties in rats.

Studies on antiulcer drugs. V. Synthesis and antiulcer activity of aralkylbenzazoles

A series of 2-alkylamino-5- or 6-aralkyl-substituted benzazoles were synthesized and tested for histamine H2-receptor antagonist and anti-stress ulcer activities. These new compounds showed little or no histamine H2-receptor antagoni